Chronic Heart Failure - Pipeline Review, H2 2016

  • ID: 3946401
  • Drug Pipelines
  • 156 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AnGes MG, Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Celyad SA
  • Mast Therapeutics, Inc.
  • MORE
Chronic Heart Failure - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Chronic Heart Failure - Pipeline Review, H2 2016, provides an overview of the Chronic Heart Failure (Cardiovascular) pipeline landscape.

Chronic heart failure is a serious condition caused by the heart failing to pump enough blood around the body at the right pressure. The symptoms develop gradually. Common symptoms are cough, fatigue, weakness, faintness, loss of appetite; need to urinate at night, shortness of breath, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. Risk factors that contribute to heart failure are high blood pressure, coronary artery disease, heart attack, diabetes and alcohol use.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Chronic Heart Failure - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Heart Failure (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Heart Failure (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Chronic Heart Failure and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Discovery stages are 9, 11, 2 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively for Chronic Heart Failure.

Chronic Heart Failure (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Heart Failure (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Chronic Heart Failure (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Heart Failure (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Heart Failure (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Heart Failure (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Heart Failure (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Heart Failure (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AnGes MG, Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Celyad SA
  • Mast Therapeutics, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Chronic Heart Failure Overview

Therapeutics Development

Pipeline Products for Chronic Heart Failure - Overview

Pipeline Products for Chronic Heart Failure - Comparative Analysis

Chronic Heart Failure - Therapeutics under Development by Companies

Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes

Chronic Heart Failure - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Chronic Heart Failure - Products under Development by Companies

Chronic Heart Failure - Products under Investigation by Universities/Institutes

Chronic Heart Failure - Companies Involved in Therapeutics Development

Amgen Inc.

AnGes MG, Inc.

AstraZeneca Plc

Bayer AG

Capricor Therapeutics, Inc.

Celyad SA

Juventas Therapeutics, Inc.

Laboratoires Pierre Fabre SA

Les Laboratoires Servier SAS

Mast Therapeutics, Inc.

Mesoblast Limited

Novartis AG

Pfizer Inc.

scPharmaceuticals Inc

Stemedica Cell Technologies, Inc.

Theravance Biopharma, Inc.

Vichem Chemie Research Ltd.

Zensun (Shanghai) Sci & Tech Co., Ltd.

Chronic Heart Failure - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(sacubitril + valsartan) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

beperminogene perplasmid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C3BSCQR-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenderitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLR-325 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dapagliflozin propanediol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-373280 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

furosemide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ivabradine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JVS-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-2286 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPC-150IM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

neladenoson bialanate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neucardin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omecamtiv mecarbil MR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rivaroxaban - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-38844 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

serelaxin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chronic Heart Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1439 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vepoloxamer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vericiguat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chronic Heart Failure - Dormant Projects

Chronic Heart Failure - Discontinued Products

Chronic Heart Failure - Product Development Milestones

Featured News & Press Releases

Sep 19, 2016: Important new analysis shows that Novartis Entresto is associated with higher relative health-related quality of life scores among HFrEF patients

Sep 19, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA Annual Scientific Meeting

Sep 12, 2016: AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure

Sep 09, 2016: Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the HFSA Annual Scientific Meeting

Sep 01, 2016: Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development

Aug 28, 2016: CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications

Jul 01, 2016: Mesoblast Provides Update On Heart Failure Trial And Funding Of Clinical Operations

Jun 28, 2016: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy

Jun 22, 2016: Timely use of Novartis Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology

Jun 14, 2016: Mesoblast Provides Update On Global Heart Failure Program

May 23, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress

May 23, 2016: Results of Vepoloxamer Nonclinical Studies in Advanced Heart Failure Presented at European Society of Cardiology 3rd World Congress on Acute Heart Failure

May 13, 2016: Cytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016

Apr 26, 2016: NICE gives green light to new drug set to benefit 100,000 people with common heart condition

Apr 26, 2016: Celyad receives certification for C-Cure non-clinical data from the European Medicines Agency

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Chronic Heart Failure, H2 2016

Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Chronic Heart Failure - Pipeline by Amgen Inc., H2 2016

Chronic Heart Failure - Pipeline by AnGes MG, Inc., H2 2016

Chronic Heart Failure - Pipeline by AstraZeneca Plc, H2 2016

Chronic Heart Failure - Pipeline by Bayer AG, H2 2016

Chronic Heart Failure - Pipeline by Capricor Therapeutics, Inc., H2 2016

Chronic Heart Failure - Pipeline by Celyad SA, H2 2016

Chronic Heart Failure - Pipeline by Juventas Therapeutics, Inc., H2 2016

Chronic Heart Failure - Pipeline by Laboratoires Pierre Fabre SA, H2 2016

Chronic Heart Failure - Pipeline by Les Laboratoires Servier SAS, H2 2016

Chronic Heart Failure - Pipeline by Mast Therapeutics, Inc., H2 2016

Chronic Heart Failure - Pipeline by Mesoblast Limited, H2 2016

Chronic Heart Failure - Pipeline by Novartis AG, H2 2016

Chronic Heart Failure - Pipeline by Pfizer Inc., H2 2016

Chronic Heart Failure - Pipeline by scPharmaceuticals Inc, H2 2016

Chronic Heart Failure - Pipeline by Stemedica Cell Technologies, Inc., H2 2016

Chronic Heart Failure - Pipeline by Theravance Biopharma, Inc., H2 2016

Chronic Heart Failure - Pipeline by Vichem Chemie Research Ltd., H2 2016

Chronic Heart Failure - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Chronic Heart Failure - Dormant Projects, H2 2016

Chronic Heart Failure - Dormant Projects (Contd..1), H2 2016

Chronic Heart Failure - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Chronic Heart Failure, H2 2016

Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Amgen Inc.
AnGes MG, Inc.
AstraZeneca Plc
Bayer AG
Capricor Therapeutics, Inc.
Celyad SA
Juventas Therapeutics, Inc.
Laboratoires Pierre Fabre SA
Les Laboratoires Servier SAS
Mast Therapeutics, Inc.
Mesoblast Limited
Novartis AG
Pfizer Inc.
scPharmaceuticals Inc
Stemedica Cell Technologies, Inc.
Theravance Biopharma, Inc.
Vichem Chemie Research Ltd.
Zensun (Shanghai) Sci & Tech Co., Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll